Wellcome Trust Invests in Kymab | July 19, 2010 Issue - Vol. 88 Issue 29 | Chemical & Engineering News
Volume 88 Issue 29 | p. 19 | Concentrates
Issue Date: July 19, 2010

Wellcome Trust Invests in Kymab

Department: Business
Keywords: Kymab, Sanger Institute, monoclonal antibodies

Kymab, a Cambridge, England-based bio­pharmaceutical firm, has snagged $30 million from Wellcome Trust’s investment division in its first round of financing. Kymab was spun off from the labs of Allan Bradley, director emeritus of Wellcome Trust Sanger Institute. Kymab owns monoclonal antibody development technology that uses mice whose engineered chromosomes endow them with the B lymphocyte component of the human immune system. The company says its technology should enable a diverse array of highly selective, potent, and well-tolerated antibody-based drugs.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment